SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?

被引：0
|
作者：
Mahmoud Al Rifai
L. Kristin Newby
Ajith P. Nair
Arunima Misra
Joseph G. Rogers
Savitri Fedson
Salim S. Virani
机构：
[1] Baylor College of Medicine,Section of Cardiology, Department of Medicine
[2] Duke University School of Medicine,Department of Medicine, Division of Cardiology
[3] Duke University School of Medicine,Duke Clinical Research Institute
[4] Texas Heart Institute,Division of Cardiology
[5] Section of Cardiology,undefined
[6] Michael E. DeBakey Veterans Affairs Medical Center,undefined
来源：
Current Atherosclerosis Reports | 2022年 / 24卷
关键词：
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i); Heart failure (HF); Heart failure with preserved ejection fraction (HFpEF); Heart failure with reduced ejection fraction (HFrEF);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：627 / 634
页数：7
相关论文
共 50 条
  • [41] Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure
    Milton Packer
    Nature Reviews Cardiology, 2022, 19 : 499 - 500
  • [42] SGLT-2 inhibitors in the treatment of heart failure with reduced ejection fraction: a systematic review
    Paffer, Pedro Toscano
    Bezerra de Albuquerque Cortez, Isabelly Regina
    Damasso Lisboa Costa, Marcelo Danilo
    da Costa Neta, Maria Rosalia
    Tavares Pedroza Monteiro, Marina Lins
    Paffer, Matheus Toscano
    Terra Lopes, Vitoria Maria
    de Paffer Filho, Silvio Hock
    AMERICAN HEART JOURNAL, 2021, 242 : 167 - 167
  • [43] SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
    Lam, Carolyn S. P.
    Chandramouli, Chanchal
    Ahooja, Vineeta
    Verma, Subodh
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (20):
  • [44] Overcoming clinical inertia with SGLT-2 inhibitors: Strategies to accelerate adoption in heart failure
    Crowe, Byron
    Misra, Shantum
    Lee, Clement D.
    JOURNAL OF HOSPITAL MEDICINE, 2025, 20 (01) : 67 - 70
  • [45] Limitations of Natriuretic Peptide Levels in Establishing SGLT-2 Inhibitors for Heart Failure Care
    Velazquez, Eric J.
    Reinhardt, Samuel W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (18) : 2086 - 2088
  • [46] DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN
    Ahmed, Mohamed
    McKenna, Malachi J.
    Crowley, Rachel K.
    ENDOCRINE PRACTICE, 2017, 23 (04) : 506 - 508
  • [47] SGLT-2 inhibitors: A step forward in the treatment of heart failure with reduced ejection fraction
    Silva-Cardoso, Jose
    Andrade, Aurora
    Brito, Dulce
    Ferreira, Jorge
    Fonseca, Candida
    Peres, Marisa
    Franco, Fatima
    Moura, Brenda
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2021, 40 (09) : 687 - 693
  • [48] SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?
    Verbrugge F.H.
    Vangoitsenhoven R.
    Mullens W.
    Van der Schueren B.
    Mathieu C.
    Tang W.H.W.
    Current Cardiovascular Risk Reports, 2015, 9 (8)
  • [49] The failure of torcetrapib: What have we learned?
    Joy, T. R.
    Hegele, R. A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) : 1379 - 1381
  • [50] SIDE EFFECTS OF SGLT-2 INHIBITORS IN PATIENTS WITH HEART FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Pozzi, A.
    Cirelli, C.
    Merlo, A.
    Scangiuzzi, C.
    Rea, F.
    Tavano, E.
    Iorio, A.
    Giovanni, C.
    Senni, M.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25
12345